Jennifer Sceppa, MD
Dermatology · Lancaster, PANPI 1730135450
Payments from drug & device makers
Across 98 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$366
- Novartis$292
- AbbVie$286
- E.r. Squibb & Sons, L.L.C.$265
- Sun Pharmaceutical Industries Inc.$146
- Pfizer$125
- plus $530 from 10 others
What the payments were for
- Food & beverage$1,63781%
- Education$37319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $366 |
| Novartis | 17 | $292 |
| AbbVie | 15 | $286 |
| E.r. Squibb & Sons, L.L.C. | 16 | $265 |
| Sun Pharmaceutical Industries Inc. | 4 | $146 |
| Pfizer | 6 | $125 |
| LEO Pharma Inc. | 4 | $96 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Incyte Corporation | 4 | $74 |
| Galderma Laboratories, L.p. | 4 | $60 |
| Organon | 8 | $56 |
| Strata Skin Sciences, Inc. | 4 | $48 |
| Lilly USA, LLC | 2 | $40 |
| UCB, Inc. | 2 | $38 |
| Mayne Pharma Commercial LLC | 2 | $26 |
| Stemline Therapeutics Inc. | 1 | $13 |
How this compares
$2,011 in reported general payments places this provider in the 50th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $41,163 |
| Clobetasol Propionate | 52 | $2,724 |
| Metronidazole | 28 | $1,573 |
| Fluorouracil | 25 | $1,526 |
| Mycophenolate Mofetil | 25 | $1,255 |
| Triamcinolone Acetonide | 81 | $944 |
| Doxycycline Hyclate | 33 | $699 |
| Betamethasone Dipropionate | 13 | $520 |
| Hydroxychloroquine Sulfate | 15 | $483 |
| Clindamycin Phosphate | 12 | $314 |
| Ketoconazole | 29 | $308 |
| Mupirocin | 40 | $297 |
| ValacyclovirValacyclovir Hcl | 31 | $213 |
| Nystatin | 12 | $183 |
| Prednisone | 14 | $121 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Lancaster
- Stephanie MackeyLancaster$104K
- Victoria WerthPhiladelphia$7.2M
- Laura FerrisPittsburgh$4.3M
- Joel GelfandPhiladelphia$3.6M
- Scott GottliebExton$3.4M
- Lawrence ParishPhiladelphia$2.9M
- Stephen SchleicherSugarloaf$2.3M
- Douglas KressWexford$2M
- Stephen HessPhiladelphia$1.7M
- Joe TungPittsburgh$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.